Dr. Ali El-Ghamrawy: We remain committed to supporting an investment-friendly pharmaceutical environment and ensuring the availability of biological preparations for Egyptian patients.
As part of the Egyptian Drug Authority’s (EDA) ongoing efforts to enhance pharmaceutical security and support the availability of priority biological medicinal products for Egyptian patients, the Authority held an official meeting with a high-level delegation from GlaxoSmithKline (GSK).
The meeting aimed to discuss ways to expand areas of cooperation and address challenges that may affect the availability of essential pharmaceutical products in the Egyptian market.
Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority, welcomed the company’s delegation, headed by Eng. Hassan Fahmy, Chairman & Managing Director of GSK Egypt.
Both sides discussed key topics related to ensuring the availability of biological pharmaceutical products, particularly those classified as priority medicines for Egyptian patients. The GSK delegation also presented the company’s future plans in Egypt, emphasizing their commitment to expanding local manufacturing and increasing the production capacity of their Egyptian facilities—an approach that will enhance product sustainability and reduce reliance on imports.
During the meeting, the EDA Chairman stressed the Authority’s keen interest in strengthening partnerships with leading global pharmaceutical companies. He highlighted that the EDA continues to foster an attractive and supportive pharmaceutical environment based on transparency, technical guidance, and streamlined procedures—all aimed at serving patients’ interests and aligning with the state’s strategic direction in this vital sector.
He further emphasized that the EDA places special priority on ensuring the uninterrupted availability of biological pharmaceutical products in the market. This is achieved through continuous collaboration with local and international manufacturers to develop practical solutions to emerging challenges, along with close monitoring of production and supply plans.
For its part, GSK expressed appreciation for the strong cooperation with the Egyptian Drug Authority, noting that Egypt represents a key hub for its regional operations. The company reaffirmed its commitment to enhancing investments and expanding its contribution to strengthening the Egyptian pharmaceutical industry.
This meeting comes within the framework of the periodic discussions held by the Egyptian Drug Authority with its industry partners, in line with the Authority’s strategic direction to reinforce national pharmaceutical security and support Egypt’s position as a leading regional center for pharmaceutical manufacturing and distribution.